Artificial Intelligence driven Marketing Communications
NanoMed Targeting Systems Inc. is developing a market disruptive drug delivery system using nano-magnetic targeting technology to revolutionize the drug delivery.
Atrial Fibrillation (AF) is the most common heart rhythm disorder affecting about 5 million Americans.
Post-Operative AF (POAF) is the most common complication encountered after cardiac surgery.
The need for novel therapies for AF and POAF that are preventative and more effective than the current paradigm constitutes an important unmet need in modern medicine.
NanoMed Targeting Systems Inc. (NTS) is presenting a novel procedure to the treatment of AF. The procedure consists of an injectable solution containing very small magnetic particles (nanoparticles) carrying drugs that will be localized to the nerve clusters with abnormally high activity by a powerful external magnetic field. Once navigated to the targeted, these drugs will be released and inactivate the nerves, terminating the AF without the side effects associated with ablation procedures. NTS expects that after its procedure, AF will be inhibited and the need for medication will be substantially diminished.
NTS is also developing innovative solution for Post-Operative AF (POAF) which is based on injecting the nano-material into the GPs toward the end of the open-heart surgery. The nanoformulation is freshly prepared in the operating room using a proprietary sonication instrument.
NTS is pioneering the field of magnetically targeted drug delivery. The platform system is based on proprietary magnetic nano-formulations attached to therapeutic payload(s), and its non-invasive proprietary magnetic guiding system.
NTS is offering unique innovative solutions for AF and POAF, that will provide better, cost-effective solution to those two major medical problems.
NTS revenue model is based on selling the nano-formulation package for each procedure. Those packages have very high gross-margin (~80%), and are the basis of a very profitable business model.
NTS has successfully completed acute pre-clinical trials for AF and POAF. The company is now preparing to start clinical trials within.
For the treatment of AF, NTS is presenting a novel alternative to ablation that recognizes the importance of the ganglionated plexi (GP) in the formation of AF: The procedure consists of an injectable solution containing very small magnetic particles carrying drugs that will be localized to the nerve clusters by a powerful external magnetic field. Once navigated to the targeted GP these drugs will be released and inactivate the nerves terminating the AF without the side effects associated with ablation procedures. NTS expects that after its procedure, AF will be inhibited and the need for medication will be substantially diminished.
NTS solution for POAF is based on injecting the nano-material toward the end of the open-heart surgery. The procedure consists of an injectable solution containing a nanoformulation that is injected into the GPs using NTS’s proprietary injection system. The nanoformulation is freshly prepared in the operating room using a proprietary sonication instrument
Alex Harel – Founder, President & CEO – Alex Harel holds a BA degree in Science and Economics and MA degree in Labor Studies. He served for 21 years in the Israeli Air Force (IAF) as a fighter navigator, squadron commander and other senior tasks (retired as Lieutenant Colonel). Alex Harel was one of the pioneers of TQM in the IAF, and he is involved in founding and managing several start-up companies in Israel and the US.
Prof. Kenneth J. Dormer – Founder & Chairman of the Scientific Advisory Board – B.S. Cornell University- Biology; M.S., PhD UCLA- Neurophysiology; Univ. Texas- Post-Doctoral Fellow in Cardiovascular Neurophysiology; Professor of Physiology, University of Oklahoma Health Sciences Center; Professor & Chair, Integrative Physiology & Pharmacology College of Osteopathic Medicine, Liberty University, VA. Member, Oklahoma Center for Neurosciences. Originator, Oklahoma Nanotechnology Initiative and Southwest Nanotechnology Consortium (OK, TX, NM, AZ, CO). Dr. Dormer is a member of the NIH Special Emphasis Panel/Scientific Review Group for Nanotechnology. He was a Nominee for National Science Advisor to President George H.W. Bush; Oklahoma Inventor of the Year, 1987.
Prof. Dormer is responsible for leading and coordinating the nano research and development.